Are there benefits of antihypertensive therapy beyond blood pressure lowering?

Current Hypertension Reports

Volumn 12, Issue 6, 2010, Pages 440-447

  Izzo Jr , Joseph L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antihypertensive drugs; Blood pressure measurement; Blood pressure variability; Cardiovascular diseases; Central blood pressure; Clinical trials; Comorbidities; Composite outcomes; Confounding; Heterogeneity; Hypertension; Ischemic heart disease; J curve; Risk factors; Stroke; Therapeutic response variability

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; DIASTOLIC BLOOD PRESSURE; EDEMA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; POPULATION RESEARCH; POTASSIUM BLOOD LEVEL; POTASSIUM DEPLETION; REVIEW; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; WEIGHT GAIN; WHITE COAT HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL COMPETENCE; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78649905457     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0160-0     Document Type: Review

References (51)

1. WB Kannel T Gordon MJ Schwartz 1971 Systolic versus diastolic blood pressure and risk of coronary heart disease Am J Cardiol 27 335 345 1:STN:280:DyaE3M7nvFOlsQ%3D%3D 10.1016/0002-9149(71)90428-0 5572576
2. JD Neaton D Wentworth 1992 Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: Overall findings and differences by age for 316, 099 white men Arch Intern Med 152 56 64 1:STN:280: DyaK387gt1ejsw%3D%3D 10.1001/archinte.152.1.56 1728930
3. S Lewington R Clarke N Qizilbash, et al. 2002 Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903 1913 10.1016/S0140-6736(02)11911-8 12493255 (Pubitemid 35472129)
4. S Yusuf S Hawken S Ounpuu, et al. 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 937 952 10.1016/S0140-6736(04) 17018-9 15364185 (Pubitemid 39208455)
5. AV Chobanian GL Bakris HR Black, et al. 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 1206 1252 1:CAS:528:DC%2BD3sXpsVGisL4%3D 10.1161/01.HYP.0000107251.49515.c2 14656957 (Pubitemid 37553153)
6. JA Staessen JG Wang L Thijs 2001 Cardiovascular protection and blood pressure reduction: a meta-analysis Lancet 358 1305 1315 1:STN:280: DC%2BD3MngvFegsw%3D%3D 10.1016/S0140-6736(01)06411-X 11684211 (Pubitemid 33016494)
7. JG Wang JA Staessen SS Franklin, et al. 2005 Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome Hypertension 45 907 913 1:CAS:528:DC%2BD2MXjtlylsro%3D 10.1161/01.HYP.0000165020.14745.79 15837826 (Pubitemid 40628936)
8. JA Staessen Y Li L Thijs JG Wang 2005 Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials Hypertension Res 28 385 407 10.1291/hypres.28.385 (Pubitemid 41014801)
9. FH Leenen 2004 Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome Can J Cardiol 20 Suppl B 77B 82B 15309209
10. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967, 202:1028-1034.
11. Multiple risk factor intervention trial. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982, 248:1465-1477.
12. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991, 265:3255-3264.
13. JA Staessen R Fagard L Thijs, et al. 1997 Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension Lancet 350 757 764 1:STN:280:DyaK2svktlWgsQ%3D%3D 10.1016/S0140-6736(97)05381-6 9297994 (Pubitemid 27387202)
14. JL Izzo Jr D Levy HR Black 2000 Clinical advisory statement: importance of systolic blood pressure in older Americans Hypertension 35 1021 1024 10818056
15. SS Franklin WT Gustin ND Wong 1997 Hemodynamic patterns of age-related changes in blood pressure Circulation 96 308 315 1:STN:280:DyaK2sznvFKmsw%3D%3D 9236450
16. C Rosendorff HR Black CP Cannon, et al. 2007 Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation 115 2761 2788 10.1161/CIRCULATIONAHA.107.183885 17502569 This statement extends the lower BP target (<130/80 mm Hg) to ischemic heart disease (Pubitemid 46842793)
17. JA Greenberg 2003 Removing confounders from the relationship between mortality risk and systolic blood pressure at low and moderately increased systolic blood pressure J Hypertension 21 49 56 1:CAS:528:DC%2BD3sXlsV2jtA%3D%3D 10.1097/00004872-200301000-00013 (Pubitemid 36143508)
18. IC Marschner RJ Simes A Keech 2007 Biases in the identification of risk factor thresholds and J-curves Am J Epidemiol 166 824 831 10.1093/aje/kwm145 17644824 (Pubitemid 47428899)
19. L Hansson A Zanchetti SG Carruthers, et al. 1998 Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 351 1755 1762 1:CAS:528:DyaK1cXksV2qtrY%3D 10.1016/S0140-6736(98)04311-6 9635947 (Pubitemid 28269185)
20. P Sleight J Redon P Verdecchia ONTARGET Investigators, et al. 2009 Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study J Hypertens 27 1360 1369 1:CAS:528:DC%2BD1MXnsVyis7g%3D 10.1097/HJH.0b013e32832d7370 19506526
21. FH Messerli GS Panjrath 2009 The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 54 1827 1834 10.1016/j.jacc.2009.05.073 19892233
22. H Smulyan ME Safar 2000 The diastolic blood pressure in systolic hypertension Ann Intern Med 132 233 237 1:STN:280:DC%2BD3c7gsVyjtA%3D%3D 10651605
23. WB Kannel PW Wilson BH Nam, et al. 2004 A likely explanation for the J-curve of blood pressure cardiovascular risk Am J Cardiol 94 380 384 10.1016/j.amjcard.2004.04.043 15276113 (Pubitemid 38962714)
24. H Arima J Chalmers M Woodward, et al. 2006 Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial J Hypertens 24 1201 1208 1:CAS:528:DC%2BD28Xktlartbg%3D 10.1097/01.hjh.0000226212.34055.86 16685221 (Pubitemid 43772329)
25. BE de Galan V Perkovic T Ninomiya, et al. 2009 Lowering blood pressure reduces renal events in type 2 diabetes J Am Soc Nephrol 20 883 892 10.1681/ASN.2008070667 19225038
26. R Agarwal 2009 Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease Clin J Am Soc Nephrol 4 830 837 10.2215/CJN.06201208 19339424
27. ACCORD Study Group WC Cushman GW Evans, et al. 2010 Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 1575 1585 10.1056/NEJMoa1001286 20228401
28. R Kelly C Hayward A Avolio M O'Rourke 1989 Noninvasive determination of age-related changes in the human arterial pulse Circulation 80 1652 1659 1:STN:280:DyaK3c%2FptV2hug%3D%3D 2598428
29. B Williams PS Lacy SM Thom, et al. 2006 Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study Circulation 113 1213 1225 1:CAS:528:DC%2BD28XhvVektrg%3D 10.1161/CIRCULATIONAHA. 105.606962 16476843 (Pubitemid 43948020)
30. B Dahlof PS Sever NR Poulter, et al. 2005 Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 895 906 10.1016/S0140-6736(05)67185-1 16154016 (Pubitemid 41265663)
31. L Thijs JA Staessen H Celis, et al. 1999 The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects Blood Press Monit 4 77 86 1:STN:280:DyaK1MzotVOltw%3D%3D 10450117
32. RH Fagard JA Staessen L Thijs, et al. 2004 Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension J Hypertens 22 81 87 1:CAS:528: DC%2BD2cXivFyqurY%3D 10.1097/00004872-200401000-00016 15106798 (Pubitemid 38293534)
33. S Yusuf P Sleight J Pogue, et al. 2000 Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 145 153 1:STN:280:DC%2BD3c%2Fpt1emug%3D%3D 10.1056/NEJM200001203420301 10639539 (Pubitemid 30051645)
34. P Svensson U de Faire P Sleight, et al. 2001 Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy Hypertension 38 E28 E32 1:CAS:528:DC%2BD38XisVymsg%3D%3D 10.1161/hy1101.099502 11751742
35. PM Rothwell SC Howard E Dolan, et al. 2010 Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension Lancet 375 895 905 10.1016/S0140-6736(10)60308-X 20226988 This study establishes a new concept: the role of BP variability in stroke
36. S Heyden NO Borhani HA Tyroler, et al. 1985 The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension J Chronic Dis 38 281 288 1:STN:280: DyaL2M3gvVWgsA%3D%3D 10.1016/0021-9681(85)90073-6 3889027 (Pubitemid 15044145)
37. T Shafi LJ Appel ER Miller 3rd, et al. 2008 Changes in serum potassium mediate thiazide-induced diabetes Hypertension 52 1022 1029 1:CAS:528: DC%2BD1cXhsVWrt7vL 10.1161/HYPERTENSIONAHA.108.119438 18981326
38. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group 2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2981 2997 10.1001/jama.288.23.2981 (Pubitemid 35471160)
39. JT Wright Jr JL Probstfield WC Cushman, et al. 2009 ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses Arch Intern Med 169 832 842 1:CAS:528:DC%2BD1MXmt1SksrY%3D 10.1001/ archinternmed.2009.60 19433694
40. JB Kostis AC Wilson RS Freudenberger, et al. 2005 Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes Am J Cardiol 95 29 35 1:CAS:528:DC%2BD2cXhtFahs7nK 10.1016/j.amjcard.2004.08.059 15619390 (Pubitemid 40051108)
41. P Verdecchia G Reboldi F Angeli, et al. 2004 Adverse prognostic significance of new diabetes in treated hypertensive subjects Hypertension 43 963 969 1:CAS:528:DC%2BD2cXjt1Gmsb8%3D 10.1161/01.HYP.0000125726.92964.ab 15037557 (Pubitemid 38579899)
42. C Held HC Gerstein S Yusuf, et al. 2007 Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk Circulation 115 1371 1375 1:CAS:528:DC%2BD2sXislaisbw%3D 10.1161/CIRCULATIONAHA.106.661405 17339550 (Pubitemid 46648372)
43. JA Staessen L Thijs Y Li, et al. 2007 'Beyond blood pressure' means multiple risk factor intervention, not plieotrophic antihypertensive drugs Curr Opinion Cardiol 22 335 343 10.1097/HCO.0b013e3281eb8e8d (Pubitemid 46897286)
44. BR Davis JA Cutler CD Furberg, et al. 2002 Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial Ann Intern Med 137 313 320 1:CAS:528:DC%2BD38Xnt1yis7g%3D 12204014
45. K Jamerson MA Weber GL Bakris, et al. 2008 Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2417 2428 1:CAS:528:DC%2BD1cXhsVCrurjJ 10.1056/NEJMoa0806182 19052124
46. S Julius SE Kjeldsen M Weber, et al. 2004 Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2022 2031 1:CAS:528:DC%2BD2cXltVCitro%3D 10.1016/S0140-6736(04)16451-9 15207952 (Pubitemid 38781102)
47. P Weidmann C Beretta-Piccoli WH Ziegler, et al. 1978 Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension Kidney Int 14 619 632 1:CAS:528:DyaE1MXosVyrsw%3D%3D 10.1038/ki.1978.171 748673
48. SG Chrysant K Danisa DC Kem, et al. 1979 Racial differences in pressure, volume and renin interrelationships in essential hypertension Hypertension 1 136 141 1:CAS:528:DyaE1MXktVemtro%3D 399939
49. FR Buhler 1988 Antihypertensive treatment according to age, plasma renin and race Drugs 35 495 503 1:STN:280:DyaL1c3otleqtA%3D%3D 10.2165/00003495- 198835050-00001 2899494
50. FHH Leenen CE Nwachuku HR Black, et al. 2006 Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial Hypertension 48 374 384 1:CAS:528:DC%2BD28XnvFKqur0%3D 10.1161/01.HYP.0000231662.77359.de 16864749 (Pubitemid 44253729)
51. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators S Yusuf K Teo, et al. 2008 Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 1174 1183 1:STN:280: DC%2BD1cnmvFOgtA%3D%3D 10.1016/S0140-6736(08)61193-9 18757085